<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856075</url>
  </required_header>
  <id_info>
    <org_study_id>Sanofi-EFFECT-AF</org_study_id>
    <nct_id>NCT01856075</nct_id>
  </id_info>
  <brief_title>Effectiveness Study of Atrial Fibrillation</brief_title>
  <acronym>EFFECT-AF</acronym>
  <official_title>Relative Effectiveness of Dronedarone vs. Other Treatments of Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>La-ser Europe Limited</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>La-ser Europe Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international observational multicentre study to be conducted in Germany, Spain,&#xD;
      Italy and USA. The main objective of the study is to evaluate the relative effectiveness of&#xD;
      dronedarone in real world clinical practice versus other anti-arrhythmic agents of interest.&#xD;
      The design of the study is a historic-prospective cohort with dynamic exposure and stratified&#xD;
      competitive recruitment with balanced comparison groups of dronedarone versus alternative&#xD;
      antiarrhythmic drugs of interest.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline Recurrence of Atrial Fibrillation</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
    <description>Assessment of the recurrence of atrial fibrillation (change from baseline) at 3 month, 6 month, and 12-18 month of follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Cardiovascular hospitalisation</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline AV node ablation and catheter ablation for Atrial Fibrillation</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Progression to permanent Atrial Fibrillation</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Clinical progression to heart failure and left ventricular systolic dysfunction</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Congestive heart failure</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Interstitial pulmonary disease</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Liver injury/toxicity</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Renal insufficiency/failure</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Cerebrovascular accident/Stroke</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Myocardial infarction</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Torsade de pointes</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>3 month; 6 month; 12-18 month</time_frame>
    <description>Assessed at each follow-up: 3 month, 6 month, and 12-18 month</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1015</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Patients treated with dronedarone</arm_group_label>
    <description>Patients treated with dronedarone at inclusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients treated with other antiarrhythmic drugs of interest</arm_group_label>
    <description>The antiarrhythmic drugs of interest to which dronedarone will be compared are:&#xD;
Class 1a/1c antiarrhythmics&#xD;
Sotalol&#xD;
Amiodarone</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This is an international observational multicentre study to be conducted in the following&#xD;
        four countries: Germany, Spain, Italy and USA. Patients will be will be recruited from&#xD;
        cardiology clinics, both hospital and non-hospital based, depending on particulars of&#xD;
        treatment pathway of ppAF patients in each country.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient 18 years old or above&#xD;
&#xD;
          -  Patient with paroxysmal or persistent atrial fibrillation&#xD;
&#xD;
          -  Patient using an AAi (antiarrhythmic drug of interest) or dronedarone (index drug)&#xD;
&#xD;
          -  Patient's treatment changed from one AAi to another AAi or dronedarone OR from no&#xD;
             antiarrhythmic therapy to the start of AAi or dronedarone therapy during previous 6&#xD;
             months before the date of recruitment&#xD;
&#xD;
          -  Patient with at least 6 months of medical and treatment information prior to the start&#xD;
             of the index drug&#xD;
&#xD;
          -  Patient able to answer the telephone interview in a language of the participating&#xD;
             country: English, German, Italian or Spanish (with or without proxy).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with heart failure (NYHA class IV)&#xD;
&#xD;
          -  Patient with permanent Atrial Fibrillation&#xD;
&#xD;
          -  Patient with psychiatric conditions preventing the participation to the study&#xD;
             according to the physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Artak Khachatryan, PhD</last_name>
    <role>Study Director</role>
    <affiliation>LA-SER Europe</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Praxis fuer Kardiologie, Im Muehlenbach 2B</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>May 9, 2013</study_first_submitted>
  <study_first_submitted_qc>May 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <last_update_submitted>September 7, 2015</last_update_submitted>
  <last_update_submitted_qc>September 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Dronedarone</keyword>
  <keyword>Cohort</keyword>
  <keyword>Effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

